Impact of aging on the development of hepatocellular carcinoma in patients with posttransfusion chronic hepatitis C.
about
The effect of pegylated interferon-alpha2b and ribavirin combination therapy for chronic hepatitis C infection in elderly patients.Body mass index is associated with age-at-onset of HCV-infected hepatocellular carcinoma patients.Assessment of disease progression in patients with transfusion-associated chronic hepatitis C using transient elastography.Increased rate of death related to presence of viremia among hepatitis C virus antibody-positive subjects in a community-based cohort studyClinical characteristics of hepatocellular carcinoma in elderly patients.Predictive factors for 24 weeks sustained virologic response (SVR24) and viral relapse in patients treated with simeprevir plus peginterferon and ribavirinThe clinical outcomes of chronic hepatitis C in South Korea: A prospective, multicenter cohort study.Suppression of hepatocellular carcinoma development in hepatitis C patients given interferon-based antiviral therapy.A Point System to Forecast Hepatocellular Carcinoma Risk Before and After Treatment Among Persons with Chronic Hepatitis C.Prognostic factors of hepatic decompensation and hepatocellular carcinoma in patients with transfusion-acquired HCV infection.Hepatocarcinogenesis in chronic hepatitis C patients achieving a sustained virological response to interferon: significance of lifelong periodic cancer screening for improving outcomes.Liver physiology and liver diseases in the elderly.Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection.Factors associated with the initiation of alpha-interferon treatment in Medicaid patients diagnosed with hepatitis C.Characteristics of elderly hepatitis C virus-associated hepatocellular carcinoma patients.Cancer preventive effect of pegylated interferon α-2b plus ribavirin in a real-life clinical setting in Japan: PERFECT interim analysis.
P2860
Q34190390-54221A58-9110-472F-8CD1-E19C9F6C99C8Q34635064-588D37C6-F77B-46CD-A3DA-1958BE16D9ADQ35872121-6E0B8604-A8C7-4236-96AF-F6ADEFADDC0AQ36000989-94AFA80E-A0E7-4928-B555-293BFD4B0E5EQ36126670-3B62E4C0-4942-4036-B746-ECD27B0C46B1Q36488315-0A63BEE3-A898-4E0A-BBE0-A2FC53561F9FQ37226231-E7E5BB36-0496-4F7D-900C-F2EB6B350A25Q38232812-E70FED1F-93E2-491A-B8D0-D3F6081C6311Q41927269-1F2B571E-0724-4B04-A1F6-E67218792327Q42236954-E007C243-6BF1-4811-9FB1-3042A1A15963Q42250363-4CADC33A-11F3-4630-80CE-291B9EE01A89Q42780223-51A0057F-1C7C-4618-8321-272C8537FF30Q42947251-C5376BBB-F6A2-41BB-AF05-83659612A34EQ42990813-7FD93A35-8D9F-4ADC-982D-821570516A0EQ43768236-22C26F9C-6CE6-4F36-A2EB-C04574876381Q50531115-41B51AF7-72DD-4722-B685-E7C346672191
P2860
Impact of aging on the development of hepatocellular carcinoma in patients with posttransfusion chronic hepatitis C.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh
2002年學術文章
@zh-hant
name
Impact of aging on the develop ...... ansfusion chronic hepatitis C.
@en
Impact of aging on the develop ...... ansfusion chronic hepatitis C.
@nl
type
label
Impact of aging on the develop ...... ansfusion chronic hepatitis C.
@en
Impact of aging on the develop ...... ansfusion chronic hepatitis C.
@nl
prefLabel
Impact of aging on the develop ...... ansfusion chronic hepatitis C.
@en
Impact of aging on the develop ...... ansfusion chronic hepatitis C.
@nl
P2093
P2860
P356
P1433
P1476
Impact of aging on the develop ...... ansfusion chronic hepatitis C.
@en
P2093
Hiroshi Yatsuhashi
Hisayuki Hamada
Katsumi Eguchi
Keisuke Nakata
Kokichi Arisawa
Manabu Daikoku
Michiaki Koga
Michitami Yano
Osami Inoue
P2860
P304
P356
10.1002/CNCR.10662
P407
P577
2002-07-01T00:00:00Z